Paul Gooley

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search
Source:ResearchGate

Paul Raymond Gooley, BSc, PhD, is an Associate Professor in Biochemistry and Molecular Biology and a researcher at the Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Victoria, Australia since 1996.[1] He directs the Gooley Research Group at the Bio21 Molecular Science & Biotechnology Institute which specializes in nuclear magnetic resonance spectroscopy (NMR) in determining the structure and dynamics of small proteins. One of his research interests is the application of NMR methods in the exploration of metabolomics and the gut microbiome and its role in chronic fatigue syndrome.[2]

Education[edit | edit source]

  • 1982, BSc (Hon), University of New South Wales
  • 1985, PhD, University of New South Wales
  • 1987-1988, post-doctorate at Yale University

Books[edit | edit source]

  • 2014, Chapter Five in Advances in Clinical Chemistry, Vol. 66, published by Elsevier; "Metabolism in Chronic Fatigue Syndrome," by Christopher W. Armstrong, Neil R. McGregor, Henry L. Butt, and Paul R. Gooley[3] - (Full Text)

Notable studies[edit | edit source]

  • 2009, Increased d-lactic acid intestinal bacteria in patients with chronic fatigue syndrome[4] - (Full text)
  • 2012, NMR metabolic profiling of serum identifies amino acid disturbances in chronic fatigue syndrome[5] - (Abstract)
  • 2014, Metabolism in chronic fatigue syndrome[6] - (Abstract)
  • 2015, Metabolic profiling reveals anomalous energy metabolism and oxidative stress pathways in chronic fatigue syndrome patients[7] - (Abstract)
  • 2016, Widespread pain and altered renal function in ME/CFS patients[8] - (Abstract)
  • 2017, The association of fecal microbiota and fecal, blood serum and urine metabolites in myalgic encephalomyelitis/chronic fatigue syndrome[9] - (Abstract - Full test upon request)
  • 2019, Post-Exertional Malaise Is Associated with Hypermetabolism, Hypoacetylation and Purine Metabolism Deregulation in ME/CFS Cases[10] - (Full text)

Talks and interviews[edit | edit source]

Online presence[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. Flesch, Juliet (Apr 1, 2015). Transforming Biology: A History of the Department of Biochemistry and Molecular Biology at the University of Melbourne. Melbourne Univ. Publishing. ISBN 9780522867718. 
  2. "Gooley Group | Bio21 Molecular Science & Biotechnology Institute". www.bio21.unimelb.edu.au. Retrieved Jul 11, 2019. 
  3. Armstrong, CW; McGregor, NR; Butt, HL; Gooley, PR (Oct 2014), "Metabolism in chronic fatigue syndrome", Adv Clin Chem, 66: 121-72, doi:10.1016/B978-0-12-801401-1.00005-0, PMID 25344988 
  4. Sheedy, John R.; Wettenhall, Richard E. H.; Scanlon, Denis; Gooley, Paul R.; Lewis, Donald P.; McGregor, Neil; Stapleton, David I.; Butt, Henry L.; De Meirleir, Kenny L. (Jul 2009). "Increased d-lactic Acid intestinal bacteria in patients with chronic fatigue syndrome". In Vivo (Athens, Greece). 23 (4): 621–628. ISSN 0258-851X. PMID 19567398. 
  5. Armstrong, Christopher W.; McGregor, Neil R.; Sheedy, John R.; Buttfield, Ian; Butt, Henry L.; Gooley, Paul R. (2012), "NMR metabolic profiling of serum identifies amino acid disturbances in chronic fatigue syndrome", Clinica Chimica Acta, 413 (19–20): 1525–1531, doi:10.1016/j.cca.2012.06.022 
  6. Armstrong, Christopher W.; McGregor, Neil R.; Butt, Henry L.; Gooley, Paul R. (2014). "Metabolism in chronic fatigue syndrome". Advances in Clinical Chemistry. 66: 121–172. ISSN 0065-2423. PMID 25344988. 
  7. Armstrong, Christopher W.; McGregor, Neil R.; Lewis, Donald P.; Butt, Henry L.; Gooley, Paul R. (2015), "Metabolic profiling reveals anomalous energy metabolism and oxidative stress pathways in chronic fatigue syndrome patients", Metabolomics, 11 (6): 1626–1639, doi:10.1007/s11306-015-0816-5 
  8. McGregor, Neil R.; Armstrong, Christopher W.; Lewis, Donald P.; Butt, Henry L.; Gooley, Paul R. (Jul 2016). "Metabolic profiling reveals anomalous energy metabolism and oxidative stress pathways in chronic fatigue syndrome patients". Fatigue: Biomedicine, Health & Behavior. 4 (3): 132–145. doi:10.1080/21641846.2016.1207400. 
  9. Armstrong, Christopher W.; McGregor, Neil R.; Lewis, Donald P.; Butt, Henry L.; Gooley, Paul R. (2017), "The association of fecal microbiota and fecal, blood serum and urine metabolites in myalgic encephalomyelitis/chronic fatigue syndrome", Metabolomics, 13 (1), doi:10.1007/s11306-016-1145-z 
  10. McGregor, Neil R.; Armstrong, Christopher W.; Lewis, Donald P.; Gooley, Paul R. (Jul 4, 2019). "Post-Exertional Malaise Is Associated with Hypermetabolism, Hypoacetylation and Purine Metabolism Deregulation in ME/CFS Cases". Diagnostics. 9 (3): 70. doi:10.3390/diagnostics9030070. ISSN 2075-4418. 

chronic fatigue syndrome (CFS) - A controversial term, invented by the U.S. Centers for Disease Control, that generally refers to a collection of symptoms as “fatigue”. There have been multiple attempts to come up with a set of diagnostic criteria to define this term, but few of those diagnostic criteria are currently in use. Previous attempts to define this term include the Fukuda criteria and the Oxford criteria. Some view the term as a useful diagnostic category for people with long-term fatigue of unexplained origin. Others view the term as a derogatory term borne out of animus towards patients. Some view the term as a synonym of myalgic encephalomyelitis, while others view myalgic encephalomyelitis as a distinct disease.

chronic fatigue syndrome (CFS) - A controversial term, invented by the U.S. Centers for Disease Control, that generally refers to a collection of symptoms as “fatigue”. There have been multiple attempts to come up with a set of diagnostic criteria to define this term, but few of those diagnostic criteria are currently in use. Previous attempts to define this term include the Fukuda criteria and the Oxford criteria. Some view the term as a useful diagnostic category for people with long-term fatigue of unexplained origin. Others view the term as a derogatory term borne out of animus towards patients. Some view the term as a synonym of myalgic encephalomyelitis, while others view myalgic encephalomyelitis as a distinct disease.

serum - The clear yellowish fluid that remains from blood plasma after clotting factors have been removed by clot formation. (Blood plasma is simply blood that has had its blood cells removed.)

serum - The clear yellowish fluid that remains from blood plasma after clotting factors have been removed by clot formation. (Blood plasma is simply blood that has had its blood cells removed.)

metabolite - A chemical compound produced by, or involved in, metabolism. The term is often used to refer to the degradation products of drugs in the body.

myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

metabolomics - The analysis of the chemical metabolism within cells, tissues or organisms. The term is often used to refer to the full set of metabolites found in a cell in a given environment.

The information provided at this site is not intended to diagnose or treat any illness.
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history.